123 related articles for article (PubMed ID: 37470604)
1. Correlations of demographical and clinicopathological features with patient outcome of pancreatic ductal adenocarcinoma: A retrospective study (2010-2018) from a Libyan Cohort.
Eddfair MM; Abdulrahman O; Alqawi O; Assidi M; Buhmeida A; Elturki A; Jebriel A; Elfagieh M; Ermiah E
J Cancer Res Ther; 2023; 19(3):745-752. PubMed ID: 37470604
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma.
Ermiah E; Eddfair M; Abdulrahman O; Elfagieh M; Jebriel A; Al-Sharif M; Assidi M; Buhmeida A
Mol Clin Oncol; 2022 Aug; 17(2):126. PubMed ID: 35832472
[TBL] [Abstract][Full Text] [Related]
3. Demographic, clinical, and pathological features of early onset pancreatic cancer patients.
Ntala C; Debernardi S; Feakins RM; Crnogorac-Jurcevic T
BMC Gastroenterol; 2018 Sep; 18(1):139. PubMed ID: 30208959
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma.
Paniccia A; Hosokawa P; Henderson W; Schulick RD; Edil BH; McCarter MD; Gajdos C
JAMA Surg; 2015 Aug; 150(8):701-10. PubMed ID: 26062046
[TBL] [Abstract][Full Text] [Related]
5. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
6. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
7. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma.
Huang X; Li M; Zhang L; Xiong J; Lu H; Tian B
Surg Oncol; 2021 Jun; 37():101528. PubMed ID: 33611029
[TBL] [Abstract][Full Text] [Related]
9. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection.
Shiba H; Misawa T; Fujiwara Y; Futagawa Y; Furukawa K; Haruki K; Iida T; Iwase R; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4041-7. PubMed ID: 24023348
[TBL] [Abstract][Full Text] [Related]
10. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
13. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
[TBL] [Abstract][Full Text] [Related]
14. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
15. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma.
Li SS; Zhou CY; Liao R; Xiong L; Weng NN; Zhao YQ; Mason C; Gou HF; Yi C; Zhu Q
Medicine (Baltimore); 2020 Apr; 99(14):e19413. PubMed ID: 32243360
[TBL] [Abstract][Full Text] [Related]
16. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
17. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
[TBL] [Abstract][Full Text] [Related]
18. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
20. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]